On August 19, Moderna did something no biotech in its class had managed: it delivered the first positive Phase 3 topline result for an mRNA-based individualized cancer vaccine. The stock surged about 177% in a single session, the largest one-day gain in company history, adding roughly $45 billion in market value. As of September 6, shares sit near $145, pulled back from the $174.38 close that day but still up more than fivefold from their 2025 low near $22.

The clinical result was genuine. Moderna and Merck’s INTerpath-001 trial tested intismeran autogene, an individualized mRNA therapy built from each patient’s tumor mutations, in combination with Merck’s Keytruda. It met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival in patients with completely resected Stage IIB to IV melanoma. The companies have said they plan to submit for regulatory approval and present full data at an upcoming medical meeting.

Two weeks earlier, Moderna had already secured its fourth U.S. product approval. The FDA cleared mFLUSIVA on August 5, making it the first mRNA-based seasonal flu vaccine to reach the U.S. market. In a Phase 3 trial of more than 40,000 adults, mFLUSIVA delivered about 27% greater relative vaccine efficacy than a standard-dose comparator. The approval covers adults 50 and older, with accelerated approval in those 65 and up contingent on a postmarketing confirmatory study.

The combination of events has transformed the investment story. For much of 2025, Moderna was a post-pandemic company searching for its next product. Now it has a fifth approval possible by year-end, nine Phase 2 and Phase 3 intismeran studies ongoing across melanoma, lung, bladder, and renal cancers, and a commercial-scale mRNA manufacturing platform that nobody else has tested at this level.

On September 1, Moderna raised $3 billion through a convertible senior notes offering at 0% interest due 2032. The company said proceeds may support oncology growth and debt repayment.

Why This Moment Has Friction

The bear case arrived September 3, when Rothschild & Co Redburn analyst Simon Baker downgraded Moderna to Sell with an $81 target, calling the stock overvalued after the run-up. That target sits roughly 44% below the stock’s recent trading level. Insider activity over the prior three months showed more than $35 million in selling, and Moderna generated $145 million in Q2 revenue while posting a net loss of $782 million.

Full trial data from INTerpath-001 has not yet been disclosed. Without detailed hazard ratios and subgroup outcomes, pricing discussions with payers remain speculative. Intismeran requires individualized tumor sequencing, custom manufacturing, and repeat dosing alongside Keytruda, none of which is simple to scale across thousands of patients globally.

The Phase 3 result reduced biological risk. It did not remove commercial, manufacturing, or financial risk.

The Bottom Line

Moderna is no longer a COVID-vaccine company with an expensive pipeline. It is something closer to an oncology-platform company at an early commercial stage, with a newly validated mRNA cancer technology and a flu franchise entering its first selling season. The renal cell carcinoma Phase 2 readout could come before year-end, and each positive result from nine active oncology studies would expand the addressable market further.

None of that makes $145 obviously cheap. Revenue remains low, losses are large, and the full intismeran data is still ahead. But the identity shift is real, and the next major catalyst, the first detailed presentation of the melanoma trial results at a medical congress, could again define the next range for the stock.